至今尚未有HIV患者进行ABO血型不相容性肾脏移植的成功报道。我们报道一例47岁的非洲裔美国男性因HIV性肾病所致终末期肾病接受非相关供者ABO血型不容性肾脏移植，其接受了IVIg/血浆置换的预处理方案，并接受IL-2受体拮抗剂诱导联合他克莫司和霉酚酸酯维持治疗。移植后并发两次急性细胞性排斥反应（Banff Ia），经过大剂量激素的冲击治疗后排斥反应得以逆转，在其后的维持治疗中增加了激素的使用。活检中没有观察到抗体介导的排斥反应。移植后20天，患者血肌酐水平最低为2.0 mg/dL，并已经维持了半年以上。其当前的CD4计数为410cells/muL。

Campara M, West-Thielke P, Thielke J, Ommert T, Oberholzer J, Benedetti E, Kaplan B.
1 Department of Pharmacy Practice, University of Illinois at Chicago, Chicago, IL. 1 Department of Surgery, University of Illinois at Chicago, Chicago, IL.

To date, there have been no reports of successful ABO blood group incompatible renal transplantation in HIV patients. We describe a case of a 47-year-old African American man with end-stage renal disease secondary to HIV-induced nephropathy who underwent a live unrelated (spouse) donor ABO blood group incompatible transplant using an intravenous immunoglobulin/plasmapheresis preconditioning regimen with interleukin-2 receptor antagonist induction along with tacrolimus and mycophenolate mofetil maintenance. The postoperative course was complicated by two acute cellular rejection (Banff Ia) episodes that were successfully managed with corticosteroid boluses and the addition of corticosteroids to maintenance immunosuppression. Antibody-mediated rejection was not observed on biopsy. The patient reached a serum creatinine nadir of 2.0 mg/dL on postoperative day 20, which has now been maintained for 170 days. His current CD4 count was 410 cells/muL.